Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Post-Mkt 11-13 18:43:19 EST

9.37

+0.06

+0.64%

盘后9.37

+0.000.00%

17:21 EST

High9.49	Low8.95	Vol1.12M
Open9.24	D1 Closing9.31	Amplitude5.78%
Mkt Cap799.39M	Tradable Cap510.44M	Total Shares85.31M
T/O10.38M	T/O Rate2.05%	Tradable Shares54.48M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":9.37,"timestamp":1794603600000,"preClose":9.31,"halted":0,"volume":1119290,"hourTrading":{"tag":"盘后","latestPrice":9.37,"preClose":9.37,"latestTime":"17:21 EST","volume":56457,"amount":529000.565661,"timestamp":1794608476757,"change":0,"changeRate":0,"amplitude":0.03254},"delay":0,"changeRate":0.006444683136412322,"floatShares":54476100,"shares":85313401,"eps":-1.347792,"marketStatus":"Post-Mkt","change":0.06,"latestTime":"11-13 18:43:19 EST","open":9.24,"high":9.485,"low":8.947,"amount":10376796.55946,"amplitude":0.057787,"askPrice":9.5,"askSize":100,"bidPrice":9,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-1.347792,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1794618000000},"marketStatusCode":4,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":9.31,"preHourTrading":{"tag":"盘前","latestPrice":9.5,"preClose":9.31,"latestTime":"09:24 EST","volume":661,"amount":6264.538926,"timestamp":1794579899899,"change":0.19,"changeRate":0.020408,"amplitude":0.192266},"postHourTrading":{"tag":"盘后","latestPrice":9.37,"preClose":9.37,"latestTime":"17:21 EST","volume":56457,"amount":529000.565661,"timestamp":1794608476757,"change":0,"changeRate":0,"amplitude":0.03254},"volumeRatio":0.876424,"impliedVol":0.927,"impliedVolPercentile":0.51},"requestUrl":"/m/hq/s/GLUE","defaultTab":"news","newsList":[{"id":"2682394793","title":"Piper Sandler Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2682394793","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682394793?lang=en_us&edition=fundamental","pubTime":"2026-11-10 19:55","pubTimestamp":1794311752,"startTime":"0","endTime":"0","summary":"In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Monte Rosa Therapeutics, with a price target of $37.00. A...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682807184","title":"Monte Rosa Therapeutics Plans Phase 2 Gout Trial of MRT-8102 in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2682807184","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682807184?lang=en_us&edition=fundamental","pubTime":"2026-11-09 20:02","pubTimestamp":1794225758,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Plans Phase 2 Gout Trial of MRT-8102 in Q4 2026Monte Rosa Therapeutics expects to start GEMINI-1, a Phase 2 trial of MRT-8102 in gout patients, in the fourth quarter of 2026.Th","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261109:nNDL12xJ3q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","GEMG","IE00BN0W2T93.GBP","BK4585","BK4539","NDAQ","LU0314104364.USD","BK4112","GLUE","IE00BGHQF748.EUR","BCDF","LU2210150020.SGD","SG9999014013.SGD","LU2095319765.USD","SG9999014005.SGD","SG9999014039.USD","GEMI","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","BK4588","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681745006","title":"Monte Rosa Therapeutics, Inc. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2681745006","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681745006?lang=en_us&edition=fundamental","pubTime":"2026-11-06 03:01","pubTimestamp":1793905283,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings SummaryMonte Rosa Therapeutics, Inc.GLUE.OQreported quarterly adjusted earnings of 3 cents per share for the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nL5N46M2YF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GLUE","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681937027","title":"Monte Rosa Therapeutics Presents Plans for Four Phase 2 Trial Starts in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2681937027","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681937027?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:22","pubTimestamp":1793881371,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Presents Plans for Four Phase 2 Trial Starts in 2026Monte Rosa Therapeutics expects cash runway into 2029, covering multiple anticipated Phase 2 studies across its three clinic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nNDL1tKmYB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681024080","title":"Monte Rosa Therapeutics Q3 Operating Income USD -1.939 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2681024080","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681024080?lang=en_us&edition=fundamental","pubTime":"2026-11-05 20:01","pubTimestamp":1793880063,"startTime":"0","endTime":"0","summary":"BRIEF-Monte Rosa Therapeutics Q3 Operating Income USD -1.939 MillionNov 05 (Reuters) - Monte Rosa Therapeutics Q3 net income USD 3.063 million.Q3 operating expenses USD 56.305 millionQ3 collaboration revenue USD 54.366 millionQ3 pretax profit USD 3.779 million","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261105:nPLXP7Z5DG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680177257","title":"Monte Rosa Therapeutics Grants Equity Awards to Four New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2680177257","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680177257?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:01","pubTimestamp":1793739682,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics Grants Equity Awards to Four New EmployeesMonte Rosa Therapeutics granted four newly hired non-executive employees equity awards under its 2026 Inducement Plan, effective Novem","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nNDL1NW4n6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014039.USD","LU2210150020.SGD","IE00BQXX3C00.GBP","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","LU2095319765.USD","BK4112","BK4539","SG9999014013.SGD","GLUE","IE00BQXX3D17.EUR","BK4139","IE00BGHQF748.EUR","IE00BQXX3F31.USD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014021.USD","BK4585","BCDF","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2T93.GBP","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680077259","title":"Monte Rosa Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2680077259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680077259?lang=en_us&edition=fundamental","pubTime":"2026-11-04 05:01","pubTimestamp":1793739661,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nTUA20GL3Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLUE","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680751049","title":"Monte Rosa Therapeutics to Participate in Four Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2680751049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680751049?lang=en_us&edition=fundamental","pubTime":"2026-11-02 20:05","pubTimestamp":1793621117,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics to Participate in Four Investor ConferencesMonte Rosa Therapeutics management will participate in fireside chats at four investor conferences.Guggenheim's 3rd Annual Healthcare","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDL7KKfQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BQXX3C00.GBP","LU2210150020.SGD","LU2095319765.USD","SG9999014013.SGD","SG9999014039.USD","LU2210149790.SGD","BK4112","BK4139","BCDF","BK4539","NDAQ","IE00BQXX3D17.EUR","BK4127","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP","IE00BKPKM429.USD","IE00BGHQF748.EUR","PIPR","GLUE","LU0314104364.USD","IE00BN0W2W23.USD","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","LU0053671581.USD","IE00B64PRP62.GBP","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678469797","title":"Monte Rosa’s MRT-6160 Enters Phase 2 Trial in Psoriatic Arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2678469797","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678469797?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:09","pubTimestamp":1793185773,"startTime":"0","endTime":"0","summary":"Monte Rosa’s MRT-6160 Enters Phase 2 Trial in Psoriatic ArthritisNovartis initiated a second Phase 2 study of Monte Rosa Therapeutics’ MRT-6160 (DDY391) in active moderate to severe psoriatic arthriti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nNDL1tLt6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","BK4139","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","SG9999014039.USD","BK4112","LU2210150020.SGD","NDAQ","LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BCDF","BK4539","SG9999014013.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","LU2095319765.USD","BK4585","IE00BQXX3D17.EUR","IE00BQXX3C00.GBP","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678848469","title":"Monte Rosa Therapeutics - Eligible to Receive up to $2.10 Bln in Development, Regulatory, and Sales Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2678848469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678848469?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUA4N8F9W:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678812469","title":"Monte Rosa Therapeutics - Eligible for Additional Phase 2 Study Initiation Milestones for Mrt-6160 (Ddy391)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678812469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678812469?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUA4N8F9W:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLUE","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678549469","title":"Monte Rosa Therapeutics - to Co-Fund Phase 3 Development of Mrt-6160 and Share 30% of Profits and Losses in U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2678549469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678549469?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUA4N8F9W:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678466726","title":"Monte Rosa Therapeutics - to Receive Milestone Payment upon First Patient Visit in Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2678466726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678466726?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUA4N8F9W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678466037","title":"Monte Rosa Therapeutics Announces Milestone Achievement Associated with Second Phase 2 Clinical Study Initiation for Vav1-Directed Molecular Glue Degrader Mrt-6160 (Ddy391)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678466037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678466037?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUA4N8F9W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674841202","title":"Monte Rosa Therapeutics (GLUE) Receives a Buy from UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2674841202","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674841202?lang=en_us&edition=fundamental","pubTime":"2026-10-12 06:56","pubTimestamp":1791759410,"startTime":"0","endTime":"0","summary":"In a report released today, from UBS initiated coverage with a Buy rating on Monte Rosa Therapeutics and a price target of $19.00. In a report rele...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/monte-rosa-therapeutics-glue-receives-a-buy-from-ubs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/monte-rosa-therapeutics-glue-receives-a-buy-from-ubs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704752","title":"Monte Rosa Therapeutics (GLUE) Following Phase 1 Data Faces A Big Fair Value Question","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704752","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704752?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:13","pubTimestamp":1791195189,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics (GLUE) is back on investors’ radar after the company released detailed Phase 1 GFORCE-1 data for MRT-8102, a NEK7-directed degrader studied in obese subjects with elevated cardiovascular risk.\nDespite the Phase 1 GFORCE-1 update putting Monte Rosa Therapeutics back in focus, the recent trading pattern has been weak, with the share price down 24.13% over the past month and 56.97% over 90 days. However, the 1-year total shareholder return of 37.08% and 3-year total...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/monte-rosa-therapeutics-glue-following-phase-1-data-faces-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/monte-rosa-therapeutics-glue-following-phase-1-data-faces-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","GLUE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672407757","title":"Monte Rosa Therapeutics Stock In Focus After Phase 1 Data Win","url":"https://stock-news.laohu8.com/highlight/detail?id=2672407757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672407757?lang=en_us&edition=fundamental","pubTime":"2026-10-03 14:24","pubTimestamp":1791008667,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics reported positive Phase 1 GFORCE-1 results for MRT-8102, showing robust NEK7 degradation and broad reductions in inflammatory and thrombogenic biomarkers in obese subjects with elevated cardiovascular risk, with no serious adverse events and tolerability comparable with placebo over eight weeks of treatment and follow-up.\nThe breadth of biomarker effects, including hsCRP reductions of 85% and lipoprotein(a) lowering comparable with PCSK9 inhibitors without raising...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/monte-rosa-therapeutics-stock-in-focus-after-phase-1-data-wi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/monte-rosa-therapeutics-stock-in-focus-after-phase-1-data-wi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","BK4139","LENZ","BK4539","GLUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672746758","title":"Monte Rosa Grants Inducement Equity Awards to New Hires, Including Options for 86,725 Shares at $11.26","url":"https://stock-news.laohu8.com/highlight/detail?id=2672746758","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672746758?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:01","pubTimestamp":1790971273,"startTime":"0","endTime":"0","summary":"Monte Rosa grants inducement equity awards to new hires, including options for 86,725 shares at $11.26Monte Rosa Therapeutics granted inducement equity awards to five newly hired non-executive employe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL3ln5qm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014039.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","IE00BQXX3D17.EUR","BCDF","IE00BKPKM429.USD","BK4585","LU2210149790.SGD","BK4539","BK4112","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","BK4588","LU0314104364.USD","BK4139","IE00BQXX3F31.USD","NDAQ","LU2210150020.SGD","GLUE","IE00B3QW5Z07.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672103667","title":"Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Cullinan Management (CGEM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672103667","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672103667?lang=en_us&edition=fundamental","pubTime":"2026-10-02 22:00","pubTimestamp":1790949616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Monte Rosa Therapeutics (GLUE) and Cullinan Manageme...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monte-rosa-therapeutics-glue-and-cullinan-management-cgem-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGEM","LABU","GLUE","LU0128526141.USD","XLV","BK4581","BK4139","HCSG","LU0029874061.USD","XBI","BK4539","BK4585","BK4588","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672714006","title":"Wedbush Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672714006","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672714006?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:55","pubTimestamp":1790945723,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on Monte Rosa Therapeutics today and set a price target of $27.00. Currently, the analyst consensus on Mont...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-monte-rosa-therapeutics-glue-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":-0.0917},{"period":"1month","weight":-0.0586},{"period":"3month","weight":-0.3994},{"period":"6month","weight":-0.4871},{"period":"1year","weight":-0.3425},{"period":"ytd","weight":-0.4062}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.040424},{"month":2,"riseRate":0.4,"avgChangeRate":-0.031875},{"month":3,"riseRate":0.4,"avgChangeRate":0.028615},{"month":4,"riseRate":0.4,"avgChangeRate":-0.132561},{"month":5,"riseRate":0.4,"avgChangeRate":-0.001871},{"month":6,"riseRate":0.6,"avgChangeRate":0.078411},{"month":7,"riseRate":0.666667,"avgChangeRate":0.006501},{"month":8,"riseRate":0.333333,"avgChangeRate":0.056265},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.044933},{"month":10,"riseRate":0.666667,"avgChangeRate":0.18804},{"month":11,"riseRate":0.333333,"avgChangeRate":0.000467},{"month":12,"riseRate":0.4,"avgChangeRate":0.082538}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction